Aptorum Group Ltd Class A (NASDAQ:APM) — Market Cap & Net Worth
Market Cap & Net Worth: Aptorum Group Ltd Class A (APM)
Aptorum Group Ltd Class A (NASDAQ:APM) has a market capitalization of $570.06K ($570.06K) as of September 18, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #31010 globally and #6277 in its home market, demonstrating a 1101.62% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Aptorum Group Ltd Class A's stock price $8.32 by its total outstanding shares 634682 (634.68K). Also see Aptorum Group Ltd Class A (APM) total assets for a full breakdown of the balance sheet.
Aptorum Group Ltd Class A Market Cap History: 2018 to 2026
Aptorum Group Ltd Class A's market capitalization history from 2018 to 2026. Data shows change from $96.34 Million to $5.28 Million (-31.24% CAGR). Also see APM cash generation efficiency for how efficiently the company converts equity into cash flow.
Index Memberships
Aptorum Group Ltd Class A is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.66 Trillion | 0.00% | #915 of 976 |
|
NASDAQ Composite
IXIC
|
$41.69 Trillion | 0.00% | #2889 of 3165 |
Weight: Aptorum Group Ltd Class A's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Aptorum Group Ltd Class A Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Aptorum Group Ltd Class A's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check APM share price today for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
3.60x
Aptorum Group Ltd Class A's market cap is 3.60 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2018 | $96.34 Million | $383.45K | -$14.83 Million | 251.26x | N/A |
| 2019 | $100.60 Million | $535.17K | -$18.69 Million | 187.97x | N/A |
| 2020 | $15.68 Million | $911.51K | $7.07 Million | 17.20x | 2.22x |
| 2021 | $9.52 Million | $1.54 Million | -$25.05 Million | 6.17x | N/A |
| 2022 | $3.49 Million | $1.30 Million | -$9.80 Million | 2.69x | N/A |
| 2023 | $1.55 Million | $431.38K | -$2.83 Million | 3.60x | N/A |
Competitor Companies of APM by Market Capitalization
Companies near Aptorum Group Ltd Class A in the global market cap rankings as of September 18, 2026. Review tangible equity quality of Aptorum Group Ltd Class A to assess the quality of the company's equity after excluding intangible assets.
Key companies related to Aptorum Group Ltd Class A by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #187 globally with a market cap of $130.09 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #353 globally with a market cap of $78.34 Billion USD.
- CSL Ltd (AU:CSL): Ranked #457 globally with a market cap of $59.87 Billion USD ( AU$84.62 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #505 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #187 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.09 Billion | $513.26 |
| #353 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $78.34 Billion | $774.61 |
| #457 | CSL Ltd | AU:CSL | $59.87 Billion | AU$174.41 |
| #505 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $145.62 |
Aptorum Group Ltd Class A Historical Marketcap From 2018 to 2026
Between 2018 and today, Aptorum Group Ltd Class A's market cap moved from $96.34 Million to $ 5.28 Million, with a yearly change of -31.24%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $5.28 Million | +684.91% |
| 2025 | $672.76K | -62.14% |
| 2024 | $1.78 Million | +14.35% |
| 2023 | $1.55 Million | -55.49% |
| 2022 | $3.49 Million | -63.33% |
| 2021 | $9.52 Million | -39.27% |
| 2020 | $15.68 Million | -84.42% |
| 2019 | $100.60 Million | +4.41% |
| 2018 | $96.34 Million | -- |
End of Day Market Cap According to Different Sources
On Sep 17th, 2026 the market cap of Aptorum Group Ltd Class A was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $570.06K USD |
| MoneyControl | $570.06K USD |
| MarketWatch | $570.06K USD |
| marketcap.company | $570.06K USD |
| Reuters | $570.06K USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Aptorum Group Ltd Class A
Aptorum Group Limited, through its subsidiaries, a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutic products to treat oncology and infectious diseases. Its pipeline products include SACT-1, a repurposed drug candidate, which is in phase 1 clinical trial to treat neuroblastoma and other cancer types; ALS-4, a repurposed small mol… Read more